HIV-Associated Primary Effusion Lymphoma

Leitch, Heather A.; Oksenhendler, Éric

doi:10.1007/978-3-319-26857-6_6

Cited by 2 publications

(2 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No randomized trials exist. If possible, patients with primary effusion lymphoma (PEL) should be entered into clinical trials with novel treatment approaches like bortezomib [39] or other targeted therapies because of the disappointing results of 'standard' treatment with CHOP or CHOP-like regimens [40].…”

Section: Primary Effusion Lymphomamentioning

confidence: 99%

HIV-Associated Malignant Lymphoma

et al. 2017

View full text Add to dashboard Cite

Acquired immune deficiency syndrome (AIDS)-related lymphomas (ARL) still represent a relevant field of clinical research. For most histological subtypes of ARL, no optimal initial therapy has been clearly defined so far. Rituximab plus chemotherapy is feasible and effective and should be offered to all patients with CD20-positive ARL regardless of their CD4 cell count. Combination antiretroviral therapy (cART) should be given concomitantly with chemotherapy, bearing in mind potential drug-drug interactions. Appropriate treatment of ARL is determined by a number of factors such as lymphoma stage, performance status, comorbidities, histological subtype, and immunosuppression. Treatment should principally be the same as in human immunodeficiency virus (HIV)-negative lymphoma patients. In HIV-related Hodgkin's lymphoma, high cure rates have been achieved with stage-adapted treatment approaches, albeit with worse outcomes compared to immunocompetent patients.

show abstract

Section: Primary Effusion Lymphomamentioning

confidence: 99%

HIV-Associated Malignant Lymphoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Recently, Shah NN et al has reported the successful use of daratumumab, a CD38-directed human IgG1κ monoclonal antibody, to treat a case of HIV-related PEL 91. Anti-CD30 directed treatment also showed promise 92…”

Section: Clinical Managementmentioning

confidence: 99%

Hiv and Lymphoma: From Epidemiology to Clinical Management

Cattaneo

Rossi

2019

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Patients infected with human immunodeficiency virus (HIV) are at increased risk for developing both non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL). Even if this risk has decreased for NHL after the introduction of combination antiretroviral therapy (cART), they remain the most common acquired immune deficiency syndrome (AIDS)-related cancer in the developed world. They are almost always of B-cell origin, and some specific lymphoma types are more common than others. Some of these lymphoma types can occur in both HIV-uninfected and infected patients, while others preferentially develop in the context of AIDS. HIV-associated lymphoma differs from lymphoma in the HIV negative population in that they more often present with advanced disease, systemic symptoms, and extranodal involvement and are frequently associated with oncogenic viruses (Epstein-Barr virus and/or human herpesvirus-8). Before the introduction of cART, most of these patients could not tolerate the treatment strategies routinely employed in the HIV-negative population. The widespread use of cART has allowed for the delivery of full-dose and dose-intensive chemotherapy regimens with improved outcomes that nowadays can be compared to those seen in non-HIV infected patients. However, a great deal of attention should be paid to opportunistic infections and other infectious complications, cART-chemotherapy interactions, and potential cumulative toxicity. In the context of relatively sparse prospective and randomized trials, the optimal treatment of AIDS-related lymphomas remains a challenge, particularly in patients with severe immunosuppression. This paper will address epidemiology, pathogenesis, and therapeutic strategies in HIV-associated NHL and HL.

show abstract

HIV-Associated Primary Effusion Lymphoma

Cited by 2 publications

References 82 publications

HIV-Associated Malignant Lymphoma

HIV-Associated Malignant Lymphoma

Hiv and Lymphoma: From Epidemiology to Clinical Management

Contact Info

Product

Resources

About